KalVista selloff on Endpoints report unwarranted, says JonesResearch

JonesResearch caught up KalVista (KALV) management after Endpoints reported that FDA Commissioner Marty Makary had made a request to reject sebetralstat for hereditary angioedema, but was unsuccessful due to internal push back and potential legal concerns. We caught up with KALV to get any available insights. KalVista reiterated that it has not been informed of any efficacy or safety concerns by the agency’s medical reviewer team and this news comes as a surprise, the analyst tells investors in a research note. The firm says the only pending review item is the final label. “Given that no valid concern or scientific deficiency has been cited in the Endpoints article, we see recent sell off as unwarranted,” contends JonesResearch. The firm continues to expect an approval within the next couple of weeks. It has a Buy rating on KalVista with a $30 price target The tock in afternoon trading is down 2% to $11.70.